Clinical Trial Update: Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma [Phase 1]

View source ↗

Summary

Phase I study evaluating BCMA-TGF-beta CAR-T cells in relapsed or refractory multiple myeloma; trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA-TGF-beta CAR-T cells (BCMA-TGF-beta CAR-T)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Multiple Myeloma | Phase 1 | Status: NOT_YET_RECRUITING